

<b>PTO-1449 (Modified)</b>  <b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b>	<b>Attorney Docket No.:</b> TLAB.79219	<b>Serial Number:</b> 10/002,842
	<b>Applicant:</b> Boone et al.	
	<b>Filing Date:</b> 11/14/02	<b>Group:</b> <del>1845</del> 1641

**U.S. PATENT DOCUMENTS**


EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUBCLASS	FILING DATE
L/C	5,124,252	06/23/92	Guerrant et al.	435	7.24	11/28/89
	5,552,292	09/03/96	Uchida et al.	435	7.23	11/10/94
	5,455,160	10/03/95	Fagerhol et al.	435	7.23	5/27/93
L/C	6,008,335	12/28/99	Rotter et al.	536	23.1	9/19/97

**FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION**

EXAMINER INITIAL	DOCUME NT NUMBER	PUBLICATI ON DATE	COUNTRY OR PATENT OFFICE	CLA SS	SUBCLA SS	TRANSLA TION	
						YES	NO

**OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)**

L/C	Trulove SC, Witts LJ. Cortisone in Ulcerative Colities. Final Report on a Therapeutic Trial. British Medical Journal 1955; 4947:1041-1048
L/C	Baveye, S., Ellass, E., Mazurier, J., Spik, G., Legrand, D. Lactoferrine: a Multifunctional Glycoprotein Involved in the Modulation of the Inflammatory Response. Clin. Chem. Lab Med. 1999; 37(3):281-86
L/C	Suleiman S, Sonnenberg A. Cost-effectiveness of Endoscopy in Irritable Bowel Syndrome. Arch Intern Med 2001; 161:369-75
L/C	Levay, PF and Viljoen, J. Lactoferrin: a General Review. Haematologica. 1995; 80(3):256-67
L/C	Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of Disease Activity in Ulcerative Colitis by Faecal Calprotectin, a Novel Granulocyte Marker Protein. Digestion 1997; 58:176-80
L/C	Lagerholm S., Dutta SK, Merchant, NB, Nair, PP. COX-2 Expression in Fecal Colonocytes from Patients with Inflammatory Bowel Disease. Gastro 2001; 120:A16
L/C	Hammer J., Talley NJ. Diagnostic Criteria for the Irritable Bowel Syndrome. Am. J. Med. 1999; 107:5S-11S



LVC	Limburg, P.L., Ahlquist, D., & Sandborn, W., et al. Fecal Calprotectin Levels Predict Colorectal Inflammation among Patients with Chronic Diarrhea Referred for Colonoscopy. Amer. J. of Gastro. 2000; 95:2831-2837
LVC	Steiner TS, Flores CA, Pizarro TT, Guerrant RL. Fecal Lactoferrin, Interleukin-1 Beta, and Interleukin-8 Are Elevated in Patients with Severe Clostridium Difficile Colitis. Clin Diagn Lab Immunol 1997; 4:719-22
LVC	Naidu, A., Satyanarayan and Arnold R. 1997. Influence of Lactoferrin on Host-Microbe Interactions. In T. William Hutchens and Bo Lonnerdal (ed.), Lactoferrin, pp. 259-275. Humana Press
LVC	Andus T., Gross V., Caesar I., et al. PMN-elastase in Assessment of Patients with Inflammatory Bowel Disease. Dig. Dis. Sci. 1993; 35:97-105
LVC	Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate Markers of Intestinal Inflammation Are Predictive of Relapse in Patients with Inflammatory Bowel Disease. Gastroenterology 2000; 119:15-22
LVC	Dwarakanath, AD, Finnie, IA, Beesley, C M, et al. Differential Excretion of Leukocyte Granule Components in Inflammatory Bowel Disease: Implications for Pathogenesis. Clin. Sci. 1997; 92:307-313
LVC	Riley, L.W. 1995. Acute Inflammatory Diarrhea. In M. Blaser (ed.), P. Smith, J. Ravdin, H. Greenberg, and R. Guerrant, <u>Infections of the Gastrointestinal Tract</u> . Raven Press, New York, NY
LVC	Tauxe, R., and M. Cohen. 1995. Epidemiology of Diarrheal Diseases in Developed Countries. In M. Blaser, P. Smith, J. Ravdin, H. Greenberg, and R. Guerrant (ed.), <u>Infections of the Gastrointestinal Tract</u> . Raven Press, New York, NY
LVC	Sartor, R.B. 1995. Microbial Agents in Pathogenesis, Differential Diagnosis, and Complications of Inflammatory Bowel Disease. In M. Blaser, P. Smith, J. Ravdin, H. Greenberg, and R. Guerrant (ed.), <u>Infections of the Gastrointestinal Tract</u> . Raven Press, New York, NY
LVC	Mathias, JR, Clench, MH, Reeves-Darby, VG, et al. Effect of Leuprolide Acetate in Patients with Moderate to Severe Functional Bowel Disease: Double-Blind, Placebo-Controlled Study. Dig Dis Sci, 1994; 39(6):1155-62
LVC	Uchida, K., R. Matsuse, S. Tomita, K. Sugi, O. Saitoh, and S. Ohshiba. 1994. Immunochemical Detection of Human Lactoferrin in Feces as a New Marker for Inflammatory Gastrointestinal Disorders and Colon Cancer. Clin. Biochem. 27:259-264
LVC	Sugi, K., Saitoh, O., Hirata, I., and K. Katsu. 1996. Fecal Lactoferrin as a Marker for Disease Activity in Inflammatory Bowel Disease: Comparison with Other Neutrophil-derived Proteins. Amer. J. Gastroenterol. 91:927-934
LVC	Guerrant, R.L., V. Araujo, E. Soares, K. Kotloff, A. Lima, W. Cooper, and A. Lee. 1992. Measurement of Fecal Lactoferrin as a Marker of Fecal Leukocytes. J. Clin. Microbiol. 30:1238-1242



LVC ✓	Fine, K.D., F. Ogunji, J. George, M. Niehaus, and R. Guerrant. 1998. Utility of a Rapid Fecal Latex Agglutination Test Detecting the Neutrophil Protein, Lactoferrin, for Diagnosing Inflammatory Causes of Chronic Diarrhea. Amer. J. Gastroenterol. 93:1300-1305
LVC ✓	Camilleri, M. 2001. Management of Irritable Bowel Syndrome. Gastroenterol. 120:652-668
LVC ✓	Calkins, Beverly M., Everhart, J.E. Ed 1994. Inflammatory Bowel Diseases, Digestive Diseases in the United States: Epidemiology and Impact., Chapter 16, pgs. 509-550 U.S. Department of Health and Human Services, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Government Printing Office, NIH Publication No. 94-1447
LVC ✓	Sandler, Robert, Everhart, J.E. 1994. Irritable Bowel Syndrome, Digestive Diseases in the United States: Epidemiology and Impact., Chapter 19, pgs. 595-612, U.S. Department of Health and Human Services, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Government Printing Office, NIH Publication No. 94-1447
LVC ✓	Harris, J.C., H.L. DuPont, and B.R. Hornick. 1971. Fecal Leukocytes in Diarrheal Illness. Ann. Intern. Med. 76:697-703
EXAMINER <i>Olisa. X Cook</i> DATE CONSIDERED <i>10/16/03</i>	
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	